BioNTech reports Q3 2026 revenues of €1.29B, advances oncology pipeline, raises 2026 revenue guidance

BioNTech announced its third quarter 2026 financial results with revenues of €1.29 billion, driven by ongoing COVID-19 vaccine sales despite lower demand. The company highlighted progress in its oncology pipeline, including new Phase 3 trials for pumitamig and positive data for gotistobart in lung cancer. BioNTech also launched a variant-adapted COVID-19 vaccine for the 2026/2027 season and raised its full-year 2026 revenue guidance to €1.7–1.9 billion. The company remains focused on late-stage oncology programs and strategic partnerships to drive future growth.

BioNTech SE (BNTX) shares rose 2.94% to USD 90.10 as of Nov 03, 2026 19:02 WIB on Pluang. The stock trades between USD 83.89 and USD 119.34 over the past 52 weeks. Pluang investors show strong buying interest, with 100% buy orders and a typical hold time of 61 days.